

October 14, 2020

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001.

To,
The Manager – Listing,
The National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051.

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sir,

Sub: Glenmark introduces NINDANIB (Nintedanib) and is amongst the first to launch the branded generic version at an affordable cost for the treatment of Pulmonary Fibrosis in India

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited

Harish Kuber
Company Secretary & Compliance Officer

Encl: as above

Press release

For immediate distribution

Glenmark introduces NINDANIB (Nintedanib) and is amongst the first to launch the branded generic version at an affordable cost for the treatment of Pulmonary Fibrosis in India

- *Pulmonary fibrosis (PF) is a respiratory condition characterized by thickening and/or scarring of the lungs, making breathing difficult and reducing patient life spans*
- *Idiopathic (unknown cause) Pulmonary Fibrosis (IPF) affects as many as 120 Indians per million*
- *Patients with IPF are at higher risk of developing severe respiratory conditions if affected by COVID-19*
- *Glenmark's NINDANIB priced at Rs. 4500 (100 mg) and Rs. 5400 (150 mg) PER MONTH is just available at 5 % of the cost as compared to the innovator brand in India*

Mumbai, India; October 14, 2020: Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today launched NINDANIB (Nintedanib 100 and 150 mg capsules) for the treatment of pulmonary fibrosis in India. Glenmark being a leader in the area of respiratory has been amongst the first to launch the branded generic version at an affordable cost for the treatment of Pulmonary Fibrosis in India. This will provide patients a far more cost effective treatment option, and enable doctors to treat a wider patient population in the country.

Nintedanib is approved by the Indian drug regulator for the treatment of Idiopathic (unknown cause) Pulmonary Fibrosis (IPF). Since IPF is a progressive disease that gets worse over time, starting treatment early and continuing treatment are important to slow disease progression. A lower monthly treatment cost therefore becomes crucial to ensure patients adhere to prescribed treatment in the long term.

So far Nintedanib has been studied extensively in various controlled clinical trials that have established its efficacy and safety. In a recently published INBUILD[™] trial, Nintedanib showed significantly lower annual rate of decline in FVC (Forced Vital Capacity) – a measure of lung health – with various progressive fibrosing interstitial lung diseases⁴. Moreover, two clinical trials are being rolled out for to study the efficacy and safety of Nintedanib as a treatment of SARS-COV2 induced pulmonary fibrosis in Moderate to Severe COVID-19 patients.^{5,6}

“With limited treatment options available, interstitial lung diseases pose a significant treatment challenge in India. The high price of newer treatments and the pill burden of existing options only add to poor patient adherence. By introducing NINDANIB, we hope to substantially reduce both the pill and cost burden for patients in India,” said Mr. Alok Malik, Group Vice President & Business Head, India Formulations. He added, “Glenmark continues to invent and innovate healthcare solutions that meet specific and often hard-to-address needs of patients in India and the world.”

Pulmonary fibrosis (PF) is a respiratory condition characterized by the thickening and/or scarring of the lungs. This makes it difficult for oxygen to pass through the air sacs and into the bloodstream, causing symptoms such as shortness of breath and dry cough. The average survival rate in patients with IPF is poor, with only 20 to 30 percent

of people surviving at least five years after diagnosis. The most frequent cause of death is respiratory failure.² IPF typically affects men over the age of 65 in India, and most people with IPF live only three to five years post diagnosis, if left untreated.

—End—

References:

1. <https://err.ersjournals.com/content/27/150/180077>
2. Dhooria S, Agarwal R, Sehgal IS, Prasad KT, Garg M, Bal A, et al. (2018) Spectrum of interstitial lung diseases at a tertiary center in a developing country: A study of 803 subjects. PLoS ONE 13(2): e0191938. <https://doi.org/10.1371/journal.pone.0191938>
3. <https://pulmonaryfibrosisnews.com/factors-affecting-the-prognosis-of-pulmonary-fibrosis/age/#:~:text=The%20average%20survival%20in%20IPF,of%20death%20is%20respiratory%20failure.>
4. www.Clinicaltrial.gov.in
5. Flaherty K et al. N Engl J Med 2019; 381:1718-1727 DOI: 10.1056/NEJMoa1908681
6. Experimental and therapeutic medicine 20: 2557-2560, 2020
7. Data on file

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. Glenmark's key therapy focus areas globally are respiratory, dermatology and oncology. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2019). For more information, visit www.glenmarkpharma.com

For more information:

Glenmark Media Contacts

Udaykumar Murthy
Senior Manager, Corporate Communications
+91 9960377617
corpcomm@glenmarkpharma.com